Skip to Main Content

Paper Details

Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment.
Oncotarget
16
2016
Author NameAffiliation
Frederick S VizeacoumarCollege of Medicine, University of Saskatchewan, Royal University Hospital
Tanya Freywald
Zhaolei ZhangUniversity of Toronto
Zhaolei ZhangUniversity of Toronto
Franco J VizeacoumarCollege of Medicine, University of Saskatchewan, Royal University Hospital
Franco J Vizeacoumar
Andrew FreywaldCollege of Medicine, University of Saskatchewan, Royal University Hospital
  • 1 - 7

Datasets

Release 1.2